Muhammad Wasif Saif, MD, MBBS
Deputy Physician-in-Chief and
Director of Medical Oncology
Northwell Health Cancer Institute
Zucker School of Medicine
Lake Success, NY 11042, USA
Professor M. Wasif Saif has been recognized as an internationally renowned expert and Key Opinion Leader (KOL) in the fields of Gastrointestinal (GI) cancers, Experimental Therapeutics and Pharmacogenetics, an exemplary clinician, and a great teacher/mentor. He is Deputy Physician-in-Chief and Director of Medical Oncology at the Northwell Health Cancer Institute, as well as Professor of Medical Oncology in the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Up until December 2018, he served as the Professor of Medicine in Tufts Medical School and the Director of the GI Cancers Program and Program Leader of the Experimental Therapeutics Program at the Tufts Cancer Center, Boston. Over the past 18 years, he has been the principal investigator for over 65 prospective cancer clinical trials, including phase I-III studies embedded with innovative translational research components investigating host-, drug-, and/or tumor-based correlative studies. He serves on the editorial board of innumerable peer review journals, serves as a grant reviewer for competitive grants, and delivers lectures at many esteemed institutions as well as major cancer meetings. He has distinguished himself as an eminent scholar by publishing over 570 scientific papers in addition to textbook chapters and abstracts/proceedings of meetings, an extremely unique trait of him, which he considered his hobby.
His research interests include: Characterize the cellular pharmacology and determinants of sensitivity to new antineoplastic agents, and the interaction of these agents with established drugs in an effort to develop new therapies for patients with carcinomas arising in the gastrointestinal tract, Develop new analytical methods that will facilitate implementation of laboratory-based clinical studies that incorporate pharmacokinetic, pharmacodynamic, and intracellular pharmacodynamic endpoints, Utilize rational clinical pharmacology principles to assist the clinical development of investigational new drugs, Characterize the clinical pharmacokinetic profile of chemotherapeutic agents and determine if any pharmacodynamic relationships exist with efficacy or toxicity, Study the relationship between biochemical and molecular targets with response to therapy, and Develop therapeutic strategies that selectively target cancer cells with unique biochemical and/or molecular phenotypes.
HONORS AND AWARDS, SPECIAL APPOINTMENTS
• (2014) Americas Top Doctors, Castle Conolly Medical Ltd
• (2014) Americas Top Doctors for Cancer, Castle Conolly Medical Ltd
• (2013) Hero of 2013, Project Purple
• (2013) Compassionate Doctor Recognition, Vitals SM Where doctor are examined
• (2013) Americas Top Doctors, Castle Conolly Medical Ltd. 15th Ed
• (2013) Patients Choice Award, Vitals SM Where doctor are examined
• (2013) Americas Top Doctors, Castle Conolly Medical Ltd. 12th Ed
• (2013) POF Hospital Wah Award, POF Medical School and Hospital
• (2012) Americas Top Ten Doctors, Castle Conolly Medical Ltd
• (2012) Americas Top Doctors, Castle Conolly Medical Ltd. 11th Ed
• (2012) New York Metro Area Top Doctor, 2012, Castle Conolly Medical Ltd
• (2012) Top Ten Doctors, Vitlas SM Where doctor are examined
• (2012) Giovanni Verrelli Spirit Award, Project Purple for Pan Can Research
• (2012) Americas Top Oncologist, Consumers Research Council, USA
• (2012) Patients Choice Award, Vitals SM Where doctor are examined
• (2011) Americas Top Oncologist, Consumers Research Council, USA
• (2011) Compassionate Doctor Recognition, Vitals SM Where doctor are examined
• (2011) Marquis Whos Who in Medicine and Healthcare, Cancer Treatment
• (2011) Patients Choice Award, Vitals SM Where doctor are examined
• (2010) Compassionate Doctor Recognition, Vitals SM Where doctor are examined
• (2010) Leading physicians of the World, Leadership and achievement in Medicine (Top 1%-2% in each specialty)
• (2010) Americas Top Oncologist, Contribution to Cancer Care by CRC of America
• (2010) Marquis Whos Who in Medicine and Healthcare, Cancer Treatment
• (2010) Patients Choice Award, Vitals SM Where doctor are examined
• (2009) Americas Top Doctors in Cancer, Castle Conolly Medical Ltd
• (2009) Top Doctor in New Haven, CT, Outstanding Patient Care by IAI
• (2009) Yale New Haven Hospital (YNHH) Medical Staff Service Excellence Recognition High Quality Patient Compassionate Care at YNHH
• (2008 ) Ehrlich II, 150th Nobel Prize Laureate Award Meeting, Outstanding Scientist Award
• (2007) Marquis Whos Who in Medicine and Healthcare, Clinical Research
• (2007) FABB Grant for Pancreatic Cancer Research, Clinical Research
• (2007) Junior Faculty Selection for Inaugural of International Society of Gastrointestinal Cancers (ISGIO) Clinical Research
• (2005) Marquis Whos Who in America®, Research in Cancer
• (2003) VFW Ladies Auxilliary Award, UAB Cancer Center, Research in Cancer
• (2002) Junior Faculty Award, UAB Cancer Center, Translational Research in Pancreatic Cancer
• (2002) Outstanding Service Award, Cancer Care, Contribution to Cancer Care
• (2001) ASCO/AACR/NCI Workshop Award, Methods in Clinical Cancer Research
• (2001) Outstanding Service Award, Cancer Care, Contribution to Cancer Care
• (2001) AMA Physicians Recognition Award, Distinguished participation in CME
• (2001) Captain for the State of Alabama, PanCan National Month of Pancreatic Cancer Awareness
• (2000) Southern Medical Association Award, 94th Annual Scientific Session
• (2000) Mayo Clinic Fellows Award, Research in Cancer
• (1994) Certificate of Honor and Cash Award Army Directorate of Education, Pakistan
• (2011-Present) European Society of Medical Oncology (ESMO)
• (2011-Present) Pancreas Club
• (2011-Present) New York State Cancer Consortium
• (2011-Present) Pancreatic Cancer Research Team (PCRT)
• (2008-2010) CT State Medical Society (CSMG)
• (2004-Present) American College of Surgical Oncology (ACOSOG)
• (2001-2010) American Association for Cancer Research (AACR)
• (2001-2005) National Comprehensive Cancer Network (NCCN)
• (2001-Present) American Society of Pharmacology and Experimental Therapeutics (ASPET)
• (2001-2005) Member, GI Malignancies, for National Comprehensive Cancer Network (NCCN)
• (2000-Present) Southern Association for Oncology (SOA)
• (2000-Present) American Society of Clinical Oncology (ASCO)
• (1999-Present) Southern Medical Association (SMA)
• (1996-2001) American Medical Association (AMA)
• (1996-2001) American College of Physicians (ACP)
• (1993-Present) Pakistan Medical and Dental Association (PMDC)
1. Weinreb S, Saif MW, Reyes P, Lam LW, Kudesh H, Guha A. 2nd Malignancies in Chronic Lymphocytic Leukemia (CLL). Blood. 1997; 90: 304b.
2. Saif MW, Greenberg B. Dysphasia secondary to solitary plasmacytoma. Cancer Control. 1998; 5(5): 433-438.
3. Saif MW, Figg D, Reed E, Dahut W. Ascites as a manifestation of metastatic prostate cancer. Prostate Cancer and Prostate Diseases. 1999; 2(5/6): 290-293.
4. Saif MW, Hamilton M, Allegra C. Varicella Zoster virus meningitis and thrombophlebitis in patients with Hodgkins disease. Leukemia and Lymphoma. 2000; 39(3/4): 421-426.
5. Saif MW, Little R, Hamilton M, Allegra C, Wilson W. Reactivation of chronic hepatitis B following intensive chemotherapy. Annals of Oncology. 2001; 12(1): 123-129.
6. Saif MW, Bono R, Greenberg B. AIDS and Thrombosis. A study of 131 patients with HIV infection and report of thromboembolism in 10 patients. AIDS Patient Care and STDS. 2001; 15(6): 311-320.
7. Saif MW, Wilson R, Takimoto C, Grem J. Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anticancer Drugs. 2001; 12(6): 525-531.
8. Saif MW, Allegra C, Greenberg B. Bleeding diathesis in multiple myeloma. Journal of Hematopathology and Stem Cell Research. 2001; 10(5): 657-660.
9. Saif MW, Greenberg B. Hairy cell leukemia and multiple myeloma. Leukemia and Lymphoma. 2001; 42(5): 1043-1048.
10. Saif MW, Bilgrami A, Greenberg B. Incidence of second neoplasm in patients with Hairy cell leukaemia. Annals of Saudi Medicine. 2001; 21(3-4): 260-261.
11. Saif MW, Hopkins, J, Gore S. Autoimmune paraneoplastic manifestations of MDS. Leukemia and Lymphoma. 2002; 43(11): 2083-2092.
12. Guo Xiao-Du, Harold N, Saif MW M, et al. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. Cancer Chemother Pharmocol. 2003; 52(1): 79-85.
13. Engstrom P, Benson A, Choti M, et al. NCCN practice guidelines for colon cancer. JNCCN (Journal of National Comprehensive Cancer Network). 2003; 1(1): 40-53.
14. Saif MW, Quinn MG, Thomas RR, Ernst A, Grem JL. Cardiac toxicity associated with capecitabine therapy. Acta Oncologica. 2003; 42(4): 342-344.
15. Engstrom P, Benson A, Choti M, et al. NCCN practice guidelines for rectal cancer. JNCCN (Journal of National Comprehensive Cancer Network). 2003; 1(1): 54-63.
16. Engstrom P, Benson A, Choti M, et al. NCCN practice guidelines for anal canal cancer. JNCCN (Journal of National Comprehensive Cancer Network). 2003; 1(1): 64-68.
17. Levin B, Barthel J, David D, et al. NCCN practice guidelines for colorectal cancer screening. JNCCN (Journal of National Comprehensive Cancer Network). 2003; 1(1): 72-93.
18. Saif MW, Leitman SF, Cusack G, et al. Thromboembolism following removal of femoral venous apheresis catheters in patients with breast cancer. Annals of Oncology. 2004; 15(9): 1366-1372.
19. Saif MW, Wood T, McGee P, Diasio R. Peripheral neuropathy associated with capecitabine.Anticancer Drugs. 2004; 15(8): 767-771.
20. Saif MW, Joseph M, Tang S, Plants B, Russo S. Retrospective analysis of capecitabine and radiation therapy in the treatment of pancreatic cancer. The Journal of Applied Research. 2004; 4(4): 635-646.
21. Saif MW. Oral calcium ameliorating oxaliplatin-induced peripheral europathy. The Journal of Applied Research. 2004; 4(4): 576-582.
22. Muthukrishnan, Acosta-Gomez MJ, Raman A, Mahone T, Saif MW, Ojha BC. Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET-CT) in the management of pancreatic cancer. European Journal of Nuclear Medicine. 2004; 31(2): S333.
23. Ayyub M, Khan MN, Anwar M, et al. Clinicopathological features of lupus anticoagulant: experience at AFIP during last seven years. Medical Science Monitor. 2005; 11(11): CR536-CR539.
24. Engstrom P, Benson A, Choti M, et al. Chapter 1: Colon cancer. NCCN (National Comprehensive Cancer Network) Drugs and Biologics Compendium. 2005; 1: 11-17.
25. Minter A, Malik R, Ledbetter L, Winokur TS, Hawn MT, Saif MW. Colon cancer in pregnancy. Cancer Control. 2005; 12(3): 196-202.
26. Engstrom P, Benson A, Choti M, et al. Chapter 2: Rectal cancer. NCCN (National Comprehensive Cancer Network) Drugs and Biologics Compendium. 2005; 1: 18-24.
27. Engstrom P, Benson A, Choti M, et al. Chapter 3: Anal cancer. NCCN (National Comprehensive Cancer Network) Drugs and Biologics Compendium. 2005; 1: 25-28.
28. Saif MW, Alexander D, Wilcox CM. Serum alkaline phosphatase level as a prognostic tool in colorectal cancer: A study of 105 patients. The Journal of Applied Research. 2005; 5(1): 88-95.
29. Saif MW, Carpenter M, Graham Y, Sviglin H. Impact of race on outcome in pancreatic carcinoma. Journal of Pancreas (JOP). 2005; 6(3): 246-254.
30. Saif MW, Moody JS, Russo SM. Gastrointestinal bleeding associated with concurrent capecitabine and radiotherapy in patients with pancreatic cancer. Journal of Pancreas (JOP). 2005; 6(4): 325-333.
31. Saif MW. Capecitabine versus continuous-infusion 5-Fluorouracil for colorectal cancer: A retrospective efficacy and safety comparison. Clinical Colorectal Cancer. 2005; 5(2): 89-100.
32. Wright M, Morrison G, Lin PX, et al. A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors. Clinical Cancer Research. 2005; 11(11): 4144-4150. doi: 10.1158/1078-0432.CCR-04-2439
33. Saif MW, Eloubeidi MA, Russo S, et al. A phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: Expression analysis of endoscopic genes related to outcome. Journal of Clinical Oncology. 2005; 23(34): 8679-8687. doi: 10.1200/JCO.2005.02.0628
34. Blanquicett C, Saif MW, Buchsbaum DJ, et al. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: Clinical implications of abscopal effects. Clinical Cancer Research. 2005; 11 (24 Pt 1): 8773-8781. doi: 10.1158/1078-0432.CCR-05-0627
35. Posey J, Saif MW, Goetz AB, et al. Phase I study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas. Clinical Cancer Research. 2005; 11(21): 7866-7871.
36. Saif MW. An adverse interaction between warfarin and fluoropyrimidines revisited. Clinical Colorectal Cancer. 2005; 5(3): 175-180.
37. Saif MW, von Borstel R. 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice. Cancer Chemother Pharmacol. 2006; 58(1): 136-142. doi: 10.1007/s00280-005-0129-x
38. Saif MW, Mattison L, Carollo T, Ezzeldin H, Diasio RB. Dihydropyrimidine dehydrogenase deficiency in an Indian population. Cancer Chemother Pharmacol. 2006; 1-6.
39. Saif MW, Black G, Johnson M, Russo S, Diasio R. Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase. Cancer Chemother Pharmacol. 2006; 58(6): 771-775.
40. Saif MW, Diasio R. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clinical Colorectal Cancer. 2006; 5(5): 359-362.
41. Shah HR, Ledbetter L, Diasio R, Saif MW. A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. Clinical Colorectal Cancer. 2006; 5(5): 354-358. doi: 10.3816/CCC.2006.n.006
42. Curtis BR, Kaliszewski J, Marques MB, et al. Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. American Journal of Hematology. 2006; 81(3): 199-201. doi: 10.1002/ajh.20516
43. Mattison L, Fourie J, Carpenter M, et al. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clinical Cancer Research. 2006; 12(18): 5491-5495. doi: 10.1158/1078-0432.CCR-06-0747
44. Saif MW, Hashmi S, Donovan WB, Diasio RB. Peripheral Neuropathy Exacerbation Associated with Topical 5-Fluorouracil. Anticancer Drugs. 2006; 17(9): 1095-1098.
45. Saif MW, Merritt J, Robbins J, Stewart J, Schupp J. Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versusleucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma. Clinical Colorectal Cancer. 2006; 6(3): 229-234. doi: 10.3816/CCC.2006.n.042
46. Patel S, Keohan ML, Saif MW, et al. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer. 2006; 107(12): 2881-2887.
47. Saif MW, Kang SP, Chu E. Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies. Oncology (Williston Park). 2006; 20(14 Suppl 10): 11-19.
48. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opinion on Drug Safety. 2006; 5(4): 553-566. doi: 10.1517/14740322.214.171.1243
49. Cohenuram M, Saif MW. Panitumumab: The First Fully Human Monoclonal Antibody in the Treatment of Colorectal Cancer. Anti-Cancer Drugs. 2006; 18(1): 7-15.
50. Saif MW. Hypersensitivity reactions associated with oxaliplatin. Expert Opinion on Drug Safety. 2006; 5(5): 687-694.
51. Saif MW. Targeted agents for adjuvant therapy of colon cancer. Clinical Colorectal Cancer. 2006; 6(1): 46-51. doi: 10.3816/CCC.2006.n.020
52. Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB. DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol. 2007; 60(4): 503-507. doi: 10.1007/s00280-006-0392-5
53. Saif MW, Sellers S, Li M, et al. A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors. Cancer Chemother Pharmacol. 2007; 60(6): 871-882.
54. Saif MW, Fekrazad MH, Ledbetter L, Diasio RB. Hypokalemia secondary to capecitabine: a hidden toxicity? Therapeutics and clinical Risk Management. 2007; 3(1): 177-180.
55. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Annals of Surgical Oncology. 2007; 14(6): 1860-1869.
56. Wrzesinski SH, McGurk ML, Donovan CT, Ferencz TM, Saif MW. Successful desentization with incorporation of calcium gluconate and magnesium sulfate. Anti-Cancer Drugs. 2007; 18: 721-724.
57. Saif MW, Syrigos K, Mehra R, Mattison LK, Diasio RB. Dihydropyrimidine dehydrogenasedeficiency (DPD) in GI malignancies:experience of 4-years. Pakistan Journal of Medical Sciences. 2007; 23(6): 832-839.
58. Saif MW, ElfikyA. Identifying and treating fluoropyrimidine-associated cutaneous toxicity in white and non-white patients. Journal of Supportive Oncology. 2007; 5(7): 337-343.
59. Steg A, Vickers SM, Eloubeidi M, et al. Hedgehog pathway expression in heterogeneous pancreatic adenocarcinoma: implications for the molecular analysis of clinically available biopsies. Diagnostic Molecular Pathology. 2007; 16(4): 229-237.
60. Saif MW, Berk G, Cheng YC, Kinsella TJ. IPdR: a novel oral radiosensitizer. Expert Opinion in Investigational Drugs. 2007; 16(9): 1415-1424.
61. Saif MW, Kang SP, Ledbetter L, Steg A, Diasio R, Johnson M. Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation? Journal of Pancreas (JOP). 2007; 8(6): 799-805.
62. Saif MW, Black G, Roy S, et al. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. The Cancer Journal. 2007; 13(4): 247-256.
63. Saif MW, Juneja V, Black G, Thronton J, Johnson MR, Diasio RB. Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation? Supportive Cancer Therapy. 2007; 4(4): 211-218.
64. Cohenuram M, Saif MW. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. Journal of Pancreas (JOP). 2007; 8(1): 4-15.
65. Elfiky AA, Saif MW. The developing trend of monoclonal antibodies in the treatment of colorectal cancer. Expert Opinion on Biological Therapy. 2007; 7(6): 871-883.
66. Kim R, Saif MW. Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? Journal of Pancreas (JOP). 2007; 8(3): 279-288.
67. Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opinion on Drug Safety. 2007; 6(2): 175-182.
68. Saif MW, Zalonis A, Syrigos K. The clinical significance of autoantibodies in gastrointestinal malignancies: an overview. Expert Opinion on Biological Therapy. 2007; 7(4): 493-507.
69. Kang SP, Saif MW. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer-identification, prevention, and management. Journal of Supportive Oncology. 2007; 5(9): 451-457.
70. Saif MW, Kim R. Role of platinum agents in the management of advanced pancreatic cancer. Expert Opinion on Pharmacotherapy. 2007; 8(16): 2719-2727.
71. Saif MW, Karapanagiotou L, Syrigos K. Genetic alterations in pancreatic cancer. World Journal of Gastroenterology. 2007; 13(33): 4423-4430.
72. Saif MW, Tomita M, Ledbetter L, Diasio RB. Capecitabine-related cardiotoxicity: recognition and management. Journal of Supportive Oncology. 2008; 6(1): 41-48.
73. Saif MW, Manges R, Redfern C, et al. Comparative Clinical Trial to evaluate the safety and efficacy of Cofactor (CF) and 5-Fluorouracil (FU) plus bevacizumab (BV) versus leucovorin (LV) and FU plus BV in patients with metastatic colorectal carcinoma. Annals of Oncology. 2008; 19(8): viii148.
74. Saif MW, Hashmi S, Zelterman D, Almhanna K, Kim R. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. International Journal of Colorectal Diseases. 2008; 23(2): 139-145.
75. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. Journal of Clinical Oncology. 2008; 26(21): 3523-3529. doi: 10.1200/JCO.2007.15.4138
76. Saif MW, Cornfeld D, Modarresifar H, Ojha B. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients. Journal of Gastrointestinal and Liver Diseases. 2008; 17(2): 173-178.
77. Saif MW, Longo WL, Israel G. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. Clinical Colorectal Cancer. 2008; 7(2): 144-148. doi: 10.3816/CCC.2008.n.020
78. Saif MW, Merikas I, Tsimboukis S, Syrigos K. Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. Journal of Pancreas (JOP). 2008; 9(3): 267-274.
79. Kang SP, Saif MW. Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. Journal of Pancreas (JOP). 2008; 9(3): 251-266.
80. Saif MW, Sandoval A. Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity? Cutan Ocul Toxicol. 2008; 27(4): 311-315. doi: 10.1080/15569520802355774
81. Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. Anticancer Drugs. 2008; 19(5): 447-464. doi: 10.1097/CAD.0b013e3282f945aa
82. Saif MW. Management of hypomagnesemia in cancer patients receiving chemotherapy. Journal of Supportive Oncology. 2008; 6(5): 243-248.
83. Saif MW. Erlotinib: the first biologic in the management of pancreatic cancer. Expert Opinion on Pharmacotherapy. 2008; 9(9): 1595-1607. doi: 10.1517/146565126.96.36.1995
84. Saif MW. Does OPTIMOX strategy (“stop-and-go” approach) also work in treatment of pancreatic cancer with oxaliplatin-based regimens? Journal of Pancreas (JOP). 2008; 9(5): 658-663.
85. Syrigos KN, Zalonis A, Kotteas E, Saif MW. Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Review. 2008.
86. Saif MW, Seller S, Diasio RB. Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor? Journal of Pancreas (JOP). 2008; 9(2): 226-229.
87. Strimpakos A, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Review. 2008; 27(3): 495-522. doi: 10.1007/s10555-008-9134-y.
88. Syrigou E, Syrigos K, Saif MW. Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep. 2008; 8(1): 56-62. doi: 10.1007/s11882-008-0011-0
89. Damerla V, Gotlieb V, Larson H, Saif MW. Pancreatic enzyme supplementation in pancreatic cancer. Journal of Supportive Oncology. 2008; 6(8): 393-396.
90. Saif MW, Peccerillo J, Potter V. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemotherapy and Pharmacology. 2009; 63(6): 1017-1022. doi: 10.1007/s00280-008-0831-6
91. Syrigou EI, Karapanagiotou EM, Alamara CV, Boura PG, Saif MW, Syrigos KN. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clinical Colorectal Cancer. 2009; 8(2): 106-109.
92. Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opinion Drug Safety. 2009; 8 (2): 191-202.
93. Saif MW, Xyla V, Makrilia N, Bliziotis I, Syrigos KN. Thrombotic microangiopathy (TMA) associated with Gemcitabine: Rare but Real. Expert Opinion in Drug Safety. 2009; 8(3): 257-260.
94. Borad MJ, Saadati H, Lakshmipathy A, et al. Skeletal Metastases in Pancreatic Cancer: A Retrospective Study and Review of the Literature. Yale Journal of Biology and Medicine. 2009; 82(1): 1-6.
95. Saif MW, Hashmi S, Bell D, Diasio RB, Johnson MR. Prognostication of pancreatic adenocarcinoma by expression of Thymidine Phosphorylase (TP) / Dihydropyrimidine Dehydrogenase (DPD) ratio and its correlation with survival. Expert Opinion in Drug Safety. 2009; 8(5): 507-514.
96. James E, Waldron-Lynch MG, Saif MW. Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anti-Cancer Drugs. 2009; 20(7): 634-638. doi: 10.1097/CAD.0b013e32832b511e
97. Cmelak AJ, Lordick F, Borner M, Goldberg RM, Saif MW. Management of infusion reactions in clinical trials and beyond: the US and EU perspectives. Oncology (Williston Park). 2009; 23(2 Suppl 1): 18-25.
98. Saif MW, Oettle H, Vervenne WL, et al. Randomized double-blind phase II trial comparing gemcitabine plus LY203111 vs. gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. The Cancer Journal. 2009; 15(4): 339-343. doi: 10.1097/PPO.0b013e3181b36264
99. Saif MW, Syrigos KI, Hotchkiss S, et al. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 2009; 65(1): 107-112. doi: 10.1007/s00280-009-1009-6
100. Saif MW, Lansigan F, Tyler E. Flavonoids, Phenoxodiol, and a Novel Agent, Triphendiol, for the Treatment of Pancreaticobiliary Cancers. Expert Opinion in Investigational Drugs. 2009; 18(4): 469-479. doi: 10.1517/13543780902762835
101. Saif MW. Targeting cancers in the gastrointestinal tract: role of capecitabine. Onco Targets and Therapy. 2009; 29-41.
102. Tsimboukis S, Merikas I, Karapanagiotou EM, Saif MW, Syrigos KN. Erlotinib-induced skin rash in patients with non-small cell lung cancer: pathogenesis, clinical significance and management. Clinical Lung Cancer. 2009; 10(2): 106-111. doi: 10.3816/CLC.2009.n.013
103. Syrigou E, Makrilia N, Koti I, Saif MW, Syrigos KN. Hypersensitivity reactions to antineoplastic agents: an overview. Anticancer Drugs. 2009; 20(1): 1-6. doi: 10.1097/CAD.0b013e32831961b3
104. Saif MW, Dimou T, Syrigos KN. Disparities in colorectal cancer in African-American vs. Whites: before and after diagnosis. World Journal of Gastroenterology. 2009; 15(30): 3734-3743.
105. Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009; 18(3): 335-348.
106. Locher JL, Robinson CO, Bailey A, et al. The contribution of social factors to undereating in older patients with cancer. Journal of Supportive Oncology. 2009; 7(5): 168-173.
107. Saif MW, Shi N, Zelt S. Capecitabine Treatment Patterns in Patients with Gastroesophageal Cancer in the United States. World Journal of Gastroeneterology. 2009; 15(35): 4415-4422. doi: 10.3748/wjg.15.4415
108. Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev. 2009; 35(2): 148-159. doi: 10.1016/j.ctrv.2008.09.006.
109. Shahrokni A, Rajebi MR, Harold L, Saif MW. Cardiotoxicity of 5-fluorouracil and cepecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene. Journal of Pancreas (JOP). 2009; 10(2): 215-220.
110. Saif MW, Lichtman SM. Chemotherapy options and outcomes in older adult patients with colorectal cancer. Critical Reviews in Oncology and Hematology. 2009; 72(2): 155-169.
111. Saif MW. Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer. World Journal of Gastroenterology. 2009; 15(31): 3855-3864.
112. Strimpakos AS, Syrigos KN. Saif MW. Pharmacogenetics and biomarkers in colorectal cancer. Pharmacogenomics Journal. 2009; 9(3):147-160.
113. Karapanagiotou L, Syrigos K, Saif MW. Heat shock protein inhibitors and heat shock vaccines as new agents in cancer treatment. Expert Opinion on Investigatioal Drugs. 2009; 18(2): 161-174. doi: 10.1517/13543780802715792
114. Li J, Saif MW. Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. Biologics. 2009; 3: 429-441.
115. Merl M, Hoimes C, Pham T, Saif MW. Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? Expert Opinion in Investigational Drugs. 2009; 18(9):1257-1264. doi: 10.1517/13543780903136724
116. Yen Y, So S, Rose M, et al. Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Research. 2009; 29(10): 4083-4092.
117. Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. Journal of National Cancer Institute (JNCI). 2009; 101(22): 1543-1552. doi: 10.1093/jnci/djp328
118. Saif MW. Platelet count less than SHARP: What does a case series reveal? Expert Opinion on Drug Safety. 2009; 9(1): 1-8. doi: 10.1517/14740330903460317
119. Li J, Podolski N, Saif MW. Management of advanced pancreatic cancer. Expert Rev Clin Pharmacol. 2009; 2(5): 527-541.
120. Shahrokni A, Rajebi MR, Saif MW. Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? Clinical Colorectal Cancer. 2009; 8(4): 231-234. doi: 10.3816/CCC.2009.n.039
121. Locher JL, Robinson CO, Bailey FA, et al. Disruptions in the organization of meal preparation and consumption among older cancer patients and their family caregivers. Psychooncology. 2010; 19(9): 967-974.
122. Shaib W, Lee V, Saif MW. Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity. In Vivo. 2009; 23(5): 821-826.
123. Cha CH, Saif MW, Yamane BH, Weber SM. Hepatocellular carcinoma: current management. Curr Probl Surg. 2010; 47(1): 10-67.
124. Saif MW, Kaley K, Lamb L, et al. Management of Skin Toxicities of Anti-EGFR Agents in Patients with Pancreatic Cancer and Other GI Tumors by Using Electronic Communication: Effective and Convenient. Journal of Pancreas (JOP). 2010; 11(2): 176-182.
125. Saif MW, Podoltsev NA, Rubin MS, et al. Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer. Cancer Investigation. 2010; 28(2): 186-194. doi: 10.3109/07357900903179591
126. Saif MW, Lansigan F, Ruta S, et al. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine. 2010; 17(3-4): 161-169.
127. Li J, Merl M, Lee MX, Kaley K, Saif MW. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience. Expert Opinion Drug Safety. 2010; 9(2): 207-213. doi: 10.1517/14740330903555181
128. Saif MW. Colorectal cancer in review: the role of the EGFR pathway. Expert Opinion Investigational Drugs. 2010; 19(3): 357-369. doi: 10.1517/13543781003593962
129. Abalı H, Dişel U, Urün Y, Güllü I, Saif MW. How Shall We Name the Chemotherapy Administration Before and After Metastasectomy? How About “M-Neoadjuvant” and “M-Adjuvant”? Annals of Surgical Oncology. 2010; 17(7): 1970.
130. Strimpakos A, Hoimes C, Syrigos KN, Saif MW. Pancreatic cancer and personalized medicine: Can Genomics Facilitate early Diagnosis or Improve Therapeutic Outcomes? Current Pharmacogenomics and Personalized Medicine. 2010; 8(1): 73-88.
131. Saif MW, Chakerian P, Kaley K, Lamb L. First case report associating gemcitabine with hypersensitivity reaction in a patient with pancreatic cancer. Journal of Pancreas (JOP). 2010; 11(3): 273-274.
132. Dimou A, Syrigos KN, Saif MW. Is there a role for mitomycin C in metastatic colorectal cancer?. Expert Opin Investig Drugs. 2010; 19(6): 723-735.
133. Saif MW, Chu E. Biology of Colorectal Cancer. The Cancer Journal. 2010; 16(3): 1-6.
134. Saif MW, Sellers S, Diasio RB, Douillard JY. A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors. Anticancer Drugs. 2010; 21(7): 716-723.
135. Saif MW, Makrilia N, Zalonis A, Merikas M, Syrigos K. Gastric cancer in the elderly. Eur J Surg Oncol. 2010; 36(8): 709-717.
136. Merika E, Saif MW, KatzA, Syrigos K, Morse M. Colon Cancer Vaccines: An Update. In Vivo. 2010; 24(5): 607-628.
137. Saif MW, Syrigos K, Kaley K, Isufi I. The role of Pregabalin in treatment of Oxaliplatin-induced sensory neuropathy. Anticancer Research. 2010; 30(7): 2927-2933.
138. Saif MW, Syrigos K, Penney R, Kaley K. Docetaxel as Salvage Therapy in Patients with Gemcitabine-Refractory Advanced Pancreatic Cancer. Anticancer Research. 2010; 30(7): 2905-2909.
139. Reidy D, Vakiani E, Fakih MG, et al. A Randomized Phase II Study of the Insulin-Like Growth Factor-1 Receptor (IGF-1R) Inhibitor IMC-A12, with or without Cetuximab, in Patients with Cetuximab or Panitumumab-Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology (JCO). 2010; 28(27): 4240-4246.
140. Saif MW, Larson H, Kaley K, Shaib W. Chronic octreotide therapy can induce pancreatic insufficiency: a common but under-recognized adverse effect. Expert Opin Drug Saf. 2010; 9(6): 867-873.
141. Zhang W, Saif MW, Dutschman GE, et al. Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). J Chromatogr A. 2010; 1217(37): 5785-5793.
142. Bulathsinghala P, Syrigos KN, Saif MW. Role of vitamin D in the prevention of pancreatic cancer. Journal of Nutrition and Metabolism. 2010; 2010: 721365.
143. Butt W, Saadati H, Saif MW. Oxaliplatin-induced pancreatitis: a case series. Anticancer Research. 2010; 30(12): 5113-5115.
144. Saif MW. Capecitabine and hand-foot syndrome. Expert Opinionin Drug Safety. 2011; 10(2): 159-169.
145. Ghazal R, Podoltsev N, Marks P, Saif MW. Mitomycin-C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. Clinical Colorectal Cancer. 2011; 10(2): 142-145.
146. Syrigou E, Dannos I, Kotteas E, et al. Hypersensitivity Reactions to Docetaxel: Retrospective Evaluation and Development of a Desensitization Protocol. Int Arch Allergy Immunol. 2011; 156(3): 320-324.
147. Wang X, McKernan R, Kim KH, et al. Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs. 2011; 22(8): 719-731. doi: 10.1097/CAD.0b013e328346f3b4
148. Saif MW, Sarantopoulos J, Patnaik A, Tolcher AW, Takimoto C, Beeram M. Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011; 68(6): 1565-1573. doi: 10.1007/s00280-011-1639-3
149. Saif MW. Does erlotinib restore chemosensitivity to chemotherapy in pancreatic cancer? A case series. Anticancer Res. 2011; 31(3):1039-1042.
150. Zeng H, Yu H, Lu L, et al. Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer. [Funded by US National Cancer Institute, National Institutes of Health Grant 5R01-CA098870 (HAR) and Contract HHSN261200800001E (SJC), and by the Overseas Study Program of the China Scholarship Council, Beijing, China] Pancreas. 2011; 40(5): 657-663.
151. Saif MW, Rosen LS, Saito K, et al. A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil. Anticancer Res. 2011; 31(2): 625-632.
152. Dimou A, Syrigos K, Saif MW. Novel modalities in the treatment of patients with KRAS-mutated colorectal cancer. Anticancer Drugs. 2011; 22(5): 384-391. doi: 10.1097/CAD.0b013e3283439781
153. Saif MW, Chabot J. News & Views: Commentary on: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. Nature Reviews Clinical Oncology. 2011; 8(8): 452-453.
154. Russo S, OveR, Contreras C, Saif MW. Adjuvant Trials for Pancreatic Cancer: Where are we going and what is needed? Clinical Investigation. 2011; 1(5): 651-667.
155. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: a systematic review. Metal-Based Drugs. 2010; 2010.
156. Shaib W, Deng Y, Zilterman D, Lundberg B, Saif MW. Assessing Rick and Mortality of Venous Thromboembolism in Patients with Pancreatic Cancer. Anti Cancer Research. 2010; 30(10): 4261-4264.
157. Ferruci L, Black G, Thornton J, Saif MW. Nutritional Status of Patients with Locally Advanced Pancreatic Cancer Undergoing Chemoradiotherapy. Supportive Care in Cancer. 2011; 19(11): 1729-1734. doi: 10.1007/s00520-010-1011-x
158. Chaves J, Saif MW. Targetting IGFR system to treat Cancer: From Bech to Clinic. AntiCancer Drugs. 2011; 22(3): 206-212.
159. Strimpakos AS, Syrigos KN, Saif MW. The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver. 2010; 4(4): 433-449.
160. Dimou A, Syrigos K, Saif MW. Rationale for inhibition of the hedgehog pathway paracrine loop in pancreatic adenocarcinoma. Journal of Pancreas (JOP). 2011; 12(1): 1-5.
161. Zikria J, Krishnamoorthy S, Kaley K, Saif MW. Sweeping KRAS generalizations: are we depriving patients of an effective treatment? A novel KRAS mutation and dramatic response to panitumumab in a patient with metastatic colorectal cancer. Int J Colorectal Dis. 2011; 26(10): 1353-1354.
162. Saif MW, Makrilia N, Syrigos K. CoFactor: Folate Requirement for Optimization of 5-Fluouracil Activity in Anticancer Chemotherapy. Journal of Oncology. 2010; 2010: 934359. doi: 10.1155/2010/934359
163. Saif MW, Kaley K, Chu E, Copur MS. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clinical Colorectal Cancer. 2010; 9(5): 315-318. doi: 10.3816/CCC.2010.n.046.
164. Kang SP, Saif MW. Three-drug combination regimen in pancreatic cancer treatment: are we there yet? JOP. 2011; 12(2): 78-82.
165. Syrigos KN, Saif MW, Karapanagiotou EM, Oikonomopoulos G, De Marinis F. The need for third-line treatment in non-small cell lung cancer: an overview of new options. Anticancer Res. 2011; 31(2): 649-659.
166. Saif MW, Kontny E, Syrigos KN, Shahrokni A. The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series. Journal of Oncology. 2011; 2011: 125467.
167. Saif MW, Kaley K, Penney R, Hotchkiss S, Syrigos KN, Strimpakos AS. The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience. Anticancer Res. 2011; 31(9): 2971-2974.
168. Saif M, Lee Y, Kim R. Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Ther Adv Med Oncol. 2012; 4(6): 341-346. doi: 10.1177/1758834012453755
169. Dimou A, Syrigos K, Saif MW. Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. Ther Adv Med Oncol. 2012; 4(5): 271-279. doi: 10.1177/1758834012446008
170. Saif MW, Erlichman C, Dragovich T, et al. Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 2013; 71(5): 1345-1355.
171. Merika EE, Syrigos KN, Saif MW. Desmoplasia in pancreatic cancer. Can we fight it? Gastroenterol Res Pract. 2012; 781765. doi: 10.1155/2012/781765
172. Pan B, Lee Y, Rodriguez, Lee J, Saif MW. Secondary Tumors of the Pancreas: A Case Series. AntiCancer Research. 2012; 32(4): 1449-1452.
173. Saif MW. Dihydropyrimidine Dehydrogenase Gene (DPYD) Polymorphism among Caucasian and non-Caucasian Patients with 5-FU- and Capecitabine-related Toxicity Using Full Sequencing of DPYD. Cancer Genomics Proteomics. 2013; 10(2): 89-92.
174. Saif MW. Anti-VEGF Agents: Are They All Alike? Cancer Management and Research. 2013; 5: 1-13.
175. Saif MW. Mitomycin-C and Capecitabine (MIXE) as Salvage Treatment in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study. Anticancer Research. 2013; 33(6): 2743-2746.
176. Saif MW. Is there a Benefit from Addiction to Anti-VEGF Therapy in Patients with Colorectal Cancer? Anticancer Research. 2013; 33(6): 2377-2380.
177. Shahda S, Saif MW. Regorafenib: from bench to bedside in colorectal cancer. Expert Rev Clin Pharmacol. 2013; 6(3): 243-248. doi: 10.1586/ecp.13.11
178. Flores J, Saif MW. Oral taxane combination therapies: Recent Phase I Results. Clinical Investigation. 2013; 3(4): 333-341.
179. Saif MW, Ove R, Ng J, Russo S. Radiotherapy in the Management of Pancreatic Neuroendocrine Tumors (PNET): Experience at Three Institutions. Anticancer Res. 2013; 33(5): 2175-2177.
180. Saif MW, Ledbetter L, Kaley K, Garcon MC, Rodriguez T, Syrigos KN. Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma. Oncol Lett. 2014; 8(3): 1302-1306. doi: 10.3892/ol.2014.2238
181. Chu E, Haller DG, Cartwright TH, et al. Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial. Br J Cancer. 2014; 110(6): 1438-1445. doi: <br?> 182. Saif MW, Beeram M, OBrien S, et al. D.BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience. Clin Cancer Res. 2013.
183. Saif MW, Li J, Lamb L, et al. Phase II study of PHY906 plus capecitabine in pts with gemcitabine-refractory pancreatic cancer and measurement of cytokines. Cancer Chemotherapy and Pharmacology. 2013.
184. Kotteas EA, Gkiozos I, Tsagkouli S, et al. Soluble ICAM-1 levels in small-cell lung cancer: prognostic value for survival and predictive significance for response during chemotherapy. Med Oncol. 2013; 30(3): 662. doi: 10.1007/s12032-013-0662-0
185. Saif MW. Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different. Expert Opin Biol Ther. 2013; 13(11): 1489-1493. doi: 10.1517/14712598.2013.837881
186. Saif MW, Garcon MW, Rodriguez G, Rodriguez T. Bolus 5-Fluorouracil as an Alternative Modality to Infusion 5-Fluorouracil- and Capecitabine-induced Cardiotoxicity: A Case Series. In Vivo. 2013; 27(4): 531-534.
187. Saif MW. Garcon MC, Rodriguez G, Rodriguez T. A Retrospective Study of Capecitabine/Temozolomide (CAPTEM) Regimen in the Treatment of Metastatic Pancreatic Neuroendocrine Tumors (PNETs) after Failing Previous Therapy. JOP. 2013; 14(5): 498-501.
188. Saif MW. Gemcitabine as Salvage Treatment in Patients with Poorly differentiated Pancreatic Neuroendocrine Tumors. JOP. 2014; 15(1): 38-41.
189. Chen J, Elfiky A, Han M, Chen C, Saif MW. The Role of Src in Colon Cancer and Its Therapeutic Implications. Clin Colorectal Cancer. 2013.
190. Christopoulos A, Saif MW, Sarris EG, Syrigos KN. Epidemiology of active tuberculosis in lung cancer patients: a systematic review. Clin Respir J. 2013.
191. Saif MW. Pancreatic cancer: Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer. Nature Review Gastroenterol Hepatol. 2014; 11(1): 8-9.
192. Sarris EG, Harrington KJ, Saif MW, Syrigos KN. Multimodal treatment strategies for elderly patients with head and neck cancer. Cancer Treat Rev. 2013.
193. Saif MW, McConnell K, Relias V, Diasio R. Severe Toxicity with 5-FU in an African-American Patient who was carrier of DPYD gene, rs115232898 (Y186C) and rs1801265 (C29R) DPYD 3UTR SNP and 5US SNPs. Mayo Clinic Proceedings. 2014; 89(1): 131-136.
194. Ilyas S, Wasif K, Saif MW. Topical Henna Ameliorated Capecitabine-induced Hand-Foot Syndrome. Cutaneous and Ocular Toxicology. 2014; 33(3): 253-255. doi: 10.3109/15569527.2013.832280.
195. Saif MW. Advanced stage pancreatic cancer: novel therapeutic options. Expert Rev Clin Pharmacol. 2014; 7(4): 487-498. doi: 10.1586/17512433.2014.910451
196. Saif MW. MM-398 achieves primary endpoint of overall survival in phase III study in patients with gemcitabine refractory metastatic pancreatic cancer. JOP. 2014; 15(3): 278-279. doi: 10.6092/1590-8577/2507
197. Gkogkou C, Frangia K, Saif MW, Trigidou R, Syrigos K. Necrosis and apoptotic index as prognostic factors in non-small cell lung carcinoma: a review. Springerplus. 2014; 3: 120. doi: 10.1186/2193-1801-3-120
198. Krishnamoorthy SK, Saif MW. PET scanning: worth the cost in cancer? Not for all cancers–its not reliable enough yet. Oncology (Williston Park). 2014; 28(5): 391-392.
199. Khagi S, Saif MW. Pancreatic Neuroendocrine Tumors: Targeting the Molecular Basis of Disease. Current Opinions in Oncology. 2014.
200. Vyas O, Ledbetter L, Kaley K, Garcon MC, Rodriguez T, Saif MW. Clinical outcomes in pancreatic adenocarcinoma associated with brca2 mutation. Anticancer Drugs. 2014.
201. Saif MW, Ledbetter L, Kaley K, Garcon MC, Rodriguez T, Syrigos KN. Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma. Oncol Lett. 2014; 8(3): 1302-1306.
202. Saif MW, Relias V, Gunturu K. Incidence and Management of Ziv-Aflibercept Related Toxicities in Colorectal Cancer. World Journal of Clinical Oncology. 2014. doi: 10.5306/wjco.v5.i5.1028
203. Saleh M, Soltan A, Haislip S, Gilmore J, Saif MW. Second-line Therapy and Beyond: Ziv-aflibercept Treatment in Metastatic Colorectal Cancer. Clinical CRC. 2014.
204. Krishnamoorthy SK, Sebastian S, Jayaraman V, Saif MW. Incidence and Management of Regorafenib Related Toxicities in Metastatic Colorectal Cancer.
205. Chen J, Saif MW. Erlotinib plus Capecitabine as Salvage Therapy in Previously Treated Pancreatic Adenocarcinoma. Anticancer Research. 2014.